Get notified when PMVP files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Mandatory Exercise of Warrants (new) — Warrant holders are forced to exercise within 30 days of NDA acceptance or forfeit their warrants, which could cause significant dilution and selling pressure.
- Warrant Exercise Price Reset (new) — The exercise price of the common stock warrants may be reduced upon NDA acceptance, increasing the number of shares issuable and diluting existing shareholders.
PMV Pharmaceuticals prices $26.7M primary offering at $1.21/share with warrants; net proceeds $47M
Filed September 2, 2026 · ~1 min read
Key Changes
-
high
PMV Pharmaceuticals is offering 22,055,000 shares plus pre-funded warrants for 19,900,000 shares and common stock warrants for up to 41,955,000 shares at $1.21 per share.
The Offering verify on EDGAR → -
high
The company expects net proceeds of approximately $47.0 million, after underwriting discounts and expenses, to fund rezatapopt development into Q1 2028.
Use of Proceeds verify on EDGAR → -
high
The common stock warrants have an initial exercise price of $1.21, but may be reset to a lower price upon FDA acceptance of the NDA for rezatapopt, increasing potential dilution.
The Offering verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (DLTH 10-Q) is open in full — no account needed.
Partner
Trade PMVP commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify